Practical pathology-focused review of the full SDH-deficient tumor spectrum — paraganglioma-pheochromocytoma syndromes (PGL1–5), SDH-deficient GIST, SDH-deficient renal cell carcinoma, Carney-Stratakis syndrome, and Carney triad — with a stepwise diagnostic workflow integrating SDHB/SDHA IHC, morphologic cues, and molecular testing, plus guidance on which cases warrant urgent genetic counseling and family surveillance.

Targeted lipidomics in SDHB-knockdown pheochromocytoma cells revealed distinct baseline ether-phospholipid and sphingomyelin signatures versus wild-type cells; treatment with the polyamine pathway inhibitor DENSPM (N1,N11-diethylnorspermine) induced far greater lipid remodeling and caspase-3-dependent apoptosis in SDHB-deficient cells, suggesting polyamine metabolism as a previously unrecognized SDH-specific metabolic vulnerability.

Comprehensive review synthesizing multi-omics signatures in metastatic PPGL, confirming SDHB-driven pseudohypoxia and CIMP hypermethylation as primary metastatic drivers and cataloguing novel co-occurring alterations: ATRX/TERT mutations, elevated tumor mutational burden, aberrant kynurenine metabolic pathway activity, and an immunosuppressive microenvironment — all emerging as both biomarkers and candidate therapeutic targets.

Comprehensive Endocrine Reviews synthesis of epigenetic regulation across all major neuroendocrine neoplasm types — including detailed coverage of pheochromocytomas and paragangliomas — cataloguing SDHx-driven CIMP hypermethylation, ATRX/TERT alterations governing metastatic risk, histone modification patterns, and non-coding RNA dysregulation as both prognostic markers and therapeutic targets. Reviews methylation-based classifiers and circulating epigenetic biomarkers as emerging precision tools, and covers DNA methyltransferase inhibitors, HDAC inhibitors, and RNA-modifying enzyme modulators under active investigation in neuroendocrine malignancies.

Authoritative review of molecular imaging and radioligand therapy in PPGL, explaining how germline genotype (SDHx, VHL, RET, NF1, TMEM127/MAX) shapes selection among 68Ga/64Cu-DOTATATE, 18F-FDOPA, 18F-FDG, and 123I/131I-MIBG and governs eligibility for PRRT (Lu-177-DOTATATE) versus MIBG therapy. SDH-deficient PPGLs are profiled as typically high SSTR2-expressing (supporting DOTATATE imaging and PRRT) and FDG-avid (reflecting pseudohypoxic glucose upregulation), providing a practical guide to radioligand selection based on SDH-specific tumor biology.

Multi-center study of 174 PPGLs (91 patients) demonstrating that SDHx genotype and anatomical location interact significantly (p<0.001) on all DOTATATE-PET parameters: SDHx-related PPGLs show uniform high SSTR uptake regardless of anatomical location, whereas sporadic PPGLs display a cranio-caudal gradient (highest uptake in head-and-neck, substantially lower in abdominal lesions). SDHx genotype versus sporadic disease in head-and-neck PGL was discriminated with 87.3% accuracy using SSTR-PET parameters alone. These findings define an SDHx-specific SSTR-PET phenotype with direct implications for DOTATATE-PET interpretation and PRRT eligibility assessment in SDH-deficient patients regardless of tumor location.

Review of belzutifan's clinical development for pseudohypoxia-driven PPGLs, anchored by the LITESPARK-015 Phase 2 trial results: 85% disease control rate and 26% overall response rate in locally advanced or metastatic disease. Belzutifan is now the first oral and second FDA-approved therapy for metastatic PPGL, directly validating HIF-2α inhibition — the same pseudohypoxic mechanism driven by SDHx loss — as a clinical target in this disease.

Phase 1 dose-escalation study of [211At]MABG — an alpha-emitting astatine-211 MIBG analog — in 10 patients with refractory MIBG-avid pheochromocytoma or paraganglioma: no dose-limiting toxicities up to 2.1 MBq/kg, 1 partial response and 7 stable disease, with rapid systemic clearance (65% urinary excretion within 72 hours). Establishes clinical feasibility for alpha-particle MIBG therapy as a radiobiologically distinct complement to beta-particle 131I-MIBG and PRRT in MIBG-avid PPGLs.

International cohort study of 45 patients carrying the SDHC c.397C>T (p.Arg133Ter) founder variant — present in >40% of mutation-positive PGLs in French Canadians — characterizing its phenotype: 97.8% paragangliomas (59.1% head-and-neck, 27.3% thoracic, 13.6% abdominal), 11.1% metastatic disease at diagnosis, and 15.4% post-surgical recurrence over 7.9-year mean follow-up. SDHB IHC loss was confirmed in all available specimens, and the variant likely originated in France before migrating to Quebec and New England.

Phase 2 trial of rogaratinib (pan-FGFR inhibitor) in 24 patients with advanced SDH-deficient GIST achieved a 41.7% objective response rate and 31-month median progression-free survival — the strongest prospective efficacy signal yet reported for this rare disease. The mechanistic basis is that SDH-loss-driven DNA hypermethylation disrupts genomic insulator elements at the FGF3/FGF4 locus, aberrantly activating these ligands and creating an autocrine FGFR1 signaling loop selectively in SDH-deficient tumor cells.

Genome-wide CRISPR-Cas9 synthetic lethality screen in immortalized SDHB-deficient chromaffin cells identified the neddylation pathway — specifically the ubiquitin-conjugating enzyme UBE2F — as a selective vulnerability absent in normal cells. Neddylation inhibitors pevonedistat (MLN4924) and HA-9104 preferentially suppressed growth of SDHB-deficient cells, nominating the cullin-RING ligase neddylation axis as a new, unbiased drug target.

Retrospective series of 9 patients with metastatic SDH-deficient GIST who underwent complete (CC-0) cytoreductive surgery showed a median time to recurrence of 26.1 months post-CRS versus 3.4 months on the last systemic therapy before surgery. While the sample is small and patient selection was stringent, the data suggest surgical debulking may offer meaningful disease control where systemic options have exhausted.

IHC study of 57 SDH-related tumors (paraganglioma, pheochromocytoma, RCC, GIST, seminoma) from patients with confirmed germline SDH pathogenic variants found that 49% showed aberrant retained SDHB staining — divided into four atypical patterns including fine granular blush and focal retention — underscoring that SDHB IHC loss alone cannot exclude SDH deficiency and that any amount of abnormal staining should prompt genetic testing.

Systematic functional screening of somatostatin receptor agonists in SDHB-knockdown versus wild-type pheochromocytoma/paraganglioma cell lines found that SDHB-deficient cells exhibit stronger membrane SSTR2 expression and receptor internalization, and that the selective SSTR2-full agonist BIM-23120 — but not octreotide or pasireotide — selectively reduced proliferation and induced apoptosis in SDHB-deficient cells by dephosphorylating pro-survival kinase cascades. Providing a mechanistic explanation for why cold somatostatin analogs have historically failed in PPGL clinical trials while PRRT (which relies on SSTR2 binding) succeeds: SDHB deficiency specifically sensitizes tumor cells to SSTR2 full agonism, identifying this receptor subtype as a selective pharmacological vulnerability in the SDHB-deficient subset.

Comprehensive Nat Rev Clin Oncol review of HIF-2α biology and the clinical milestones of belzutifan from VHL disease through sporadic clear-cell RCC to pheochromocytoma and paraganglioma, directly validating the pseudohypoxic mechanism as a cross-tumor therapeutic target. Covers the structural basis for HIF-2α druggability, resistance mechanisms, and the rationale for extending HIF-2α inhibition to SDH-deficient and other pseudohypoxic tumor types.

In cells with SDH inhibition, pyrimidine biosynthesis is suppressed through a dual mechanism: aspartate depletion (as oxidative aspartate synthesis via the TCA cycle is lost) and direct succinate-mediated inhibition of aspartate transcarbamylase (ATCase), the enzyme committing aspartate to the pyrimidine de novo synthesis pathway. Unlike other models of aspartate limitation, SDH inhibition produces an unexpected aspartate rebound that still fails to rescue proliferation, suggesting the succinate-ATCase block is the dominant anti-proliferative mechanism — a new metabolic vulnerability with potential implications for nucleotide-synthesis-targeted therapy in SDH-deficient cancers.

Contemporary MD Anderson clinical review providing a genotype-directed treatment algorithm for metastatic pheochromocytoma and paraganglioma (MPPGL), integrating belzutifan (recently FDA-approved for MPPGL), sunitinib, cabozantinib, radiopharmaceuticals (131I-MIBG, 177Lu-DOTATATE), and chemotherapy into a clinical decision framework based on SDHx and other genotypes, catecholamine phenotype, and tumor burden. The most current comprehensive guidance for matching systemic therapy to individual patient genotype in advanced PPGL.